Boule Diagnostics AB (STU:8BD) Cyclically Adjusted Revenue per Share: €0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8BD Boule Diagnostics AB STU:8BD
47 GF Score
Price €0.48
GF Value €0.82
! 3 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Cyclically Adjusted Revenue per Share?

Boule Diagnostics AB STU:8BD 47 Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus rates STU:8BD with a GF Score™ of 47/100 and a GF Value™ of €0.82. The stock has 3 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Boule Diagnostics AB's adjusted revenue per share for the three months ended in Jun. 2026 was €0.264. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Boule Diagnostics AB's average Cyclically Adjusted Revenue Growth Rate was -3.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Boule Diagnostics AB was 10.10% per year. The lowest was 1.10% per year. And the median was 8.15% per year.

As of today (2026-07-28), Boule Diagnostics AB's current stock price is €0.48. Boule Diagnostics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €0.00. Boule Diagnostics AB's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Boule Diagnostics AB was 4.06. The lowest was 0.17. And the median was 0.69.


Boule Diagnostics AB  (STU:8BD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Boule Diagnostics AB was 4.06. The lowest was 0.17. And the median was 0.69.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Boule Diagnostics AB Cyclically Adjusted Revenue per Share Related Terms


Boule Diagnostics AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Cyclically Adjusted Revenue per Share Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 1.56 1.57 1.53 1.64

Boule Diagnostics AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.62 1.64 0.00 0.00

STU:8BD vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Boule Diagnostics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boule Diagnostics AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Boule Diagnostics AB's Cyclically Adjusted PS Ratio falls into.


STU:8BD
47GF Score
Boule Diagnostics AB STU:8BD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boule Diagnostics AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Boule Diagnostics AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.264/134.1100*134.1100
=0.264

Current CPI (Jun. 2026) = 134.1100.

Boule Diagnostics AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.418 101.138 0.554
201612 0.379 102.022 0.498
201703 0.407 102.022 0.535
201706 0.413 102.752 0.539
201709 0.422 103.279 0.548
201712 0.382 103.793 0.494
201803 0.358 103.962 0.462
201806 0.384 104.875 0.491
201809 0.388 105.679 0.492
201812 0.345 105.912 0.437
201903 0.416 105.886 0.527
201906 0.411 106.742 0.516
201909 0.445 107.214 0.557
201912 0.455 107.766 0.566
202003 0.396 106.563 0.498
202006 0.314 107.498 0.392
202009 0.335 107.635 0.417
202012 0.301 108.296 0.373
202103 0.467 108.360 0.578
202106 0.387 108.928 0.476
202109 0.395 110.338 0.480
202112 0.553 112.486 0.659
202203 0.465 114.825 0.543
202206 0.458 118.384 0.519
202209 0.436 122.296 0.478
202212 0.420 126.365 0.446
202303 0.323 127.042 0.341
202306 0.323 129.407 0.335
202309 0.308 130.224 0.317
202312 0.347 131.912 0.353
202403 0.333 132.205 0.338
202406 0.303 132.716 0.306
202409 0.296 132.304 0.300
202412 0.325 132.987 0.328
202503 0.270 132.825 0.273
202506 0.309 133.699 0.310
202509 0.297 133.480 0.298
202512 0.284 133.390 0.286
202603 0.243 133.560 0.244
202606 0.264 134.110 0.264

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Boule Diagnostics AB (STU:8BD) has a Cyclically Adjusted Revenue per Share of €0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Boule Diagnostics AB and its competitors.
Is Boule Diagnostics AB's Cyclically Adjusted Revenue per Share too high?
Boule Diagnostics AB's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Boule Diagnostics AB's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (STU:8BD) has a current Cyclically Adjusted Revenue per Share of €0.00. The stock's GF Value™ is €0.82, compared to a current price of €0.48 — trading 41.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Boule Diagnostics AB's overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Boule Diagnostics AB (STU:8BD), the current Cyclically Adjusted Revenue per Share is €0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boule Diagnostics AB (STU:8BD) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of €0.48 is trading 41.5% below its estimated GF Value™ of €0.82.

Key valuation signals for STU:8BD:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €0.82 vs. price of €0.48 (41.5% below fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the STU:8BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score

Get the complete analysis for STU:8BD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€0.82
GF Value